Abstract:8095 Background: In China, small cell lung cancer (SCLC) accounts for over 15% of lung cancers. The morbidity of SCLC has been continuously increasing. SCLC is invasive, fast-growing cancer that distinctly differs from other cancers. Approximately 70% of cases present with metastasis at diagnosis and the median overall survival rate is about 8 to 11 months with a 5-year survival rate of less than 5%. Although being sensitive to chemotherapy and radiotherapy, SCLC patients are liable to relapse and often present with drug resistance. Here we study the combination of Socazolimab, an anti-PDL1 antibody, carboplatin and etoposide to treat extensive stage small cell lung cancer. Methods: The study is a randomized, double-blinded, placebo-controlled multicenter Phase III clinical trial. Patients who have extensive-stage SCLC are eligible to the trial. Patients are randomly assigned to the study group (Socazolimab + carboplatin + etoposide) or control group (placebo + carboplatin + etoposide) at 1:1 ratio, with a treatment cycle of every 3 weeks. There are 4 cycles of chemotherapy followed by Socazolimab or placebo alone until termination events occurred or for up to 2 years. The primary endpoint is overall survival (OS). The major secondary endpoint is progression free survival (PFS). Results: There were a total of 498 patients recruited for the study with average age of 61.9 amount which 449 patients were diagnosed with stage IV SCLC. All the analysis was based on intent-to-treat (ITT). The median baseline performance status score was 1.0. The median OS of study group and control group are 13.90 months (95% CI: 12.22-15.34) and 11.58 months (95% CI: 10.64-12.81) respectively, with a P-value of 0.0316. The 24 month survival rate of study group and control group are 20.7% (95% CI:14.8-27.3) and 5.9 %(95% CI: 0.8-18.9). The median PFS of the two groups are 5.55 months (95% CI:5.06-5.82) and 4.37 months (95% CI: 4.27-4.70) with a P-value < 0.0001. The treatment related adverse event were similar in both groups. Conclusions: These results show that Socazolimab plus chemotherapy continued to provide clinically meaningful improvements in OS for patients with extensive stage small cell lung cancer. Clinical trial information: NCT04878016 .

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.

Prognostic Factors and Response of Chemotherapy Including Amrubicin in Small Cell Lung Cancer Patients

Randomized Phase III Trial of Amrubicin/cisplatin Versus Etoposide/cisplatin As First-Line Treatment for Extensive Small-Cell Lung Cancer.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Progress in the therapy of small cell lung cancer

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Efficacy of Different Monotherapies in Second-Line Treatment for Small Cell Lung Cancer: a Meta-Analysis of Randomized Controlled Trials.

Current Diagnosis and Management of Small-Cell Lung Cancer

Advances in antiangiogenic treatment of small-cell lung cancer

[Recent Advances and Future Strategies for Small Cell Lung Cancer].

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

New insights into small‐cell lung cancer development and therapy

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Complete response of esophageal small cell carcinoma amrubicin treatment

A Molecular-Directed Strategy

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

Lung Cancer Combination Treatment: Evaluation Of The Synergistic Effect Of Cisplatin Prodrug, Vinorelbine And Retinoic Acid When Co-Encapsulated In A Multi-Layered Nano-Platform

Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways